22results about "Vasoactive intestinal peptide" patented technology

The present invention is entitled Triple Agonists at the Glucagon / GLP-1 / GIP Receptor. The present invention relates to triple agonists that are active at all of the glucagon, GLP-1 and GIP receptors and uses thereof.

Provided is a fusion protein. The fusion protein simultaneously blocks a calcitonin gene-related peptide (CGRP) pathway and a pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, wherein the fusion protein comprises at least one single-domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein can simultaneously block the CGRP and PACAP pathways, thereby improving the response rate of a drug for treatment of migraine.

The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.

Provided are a recombinant microorganism expressing a vasoactive intestinal peptide (VIP) gene, and a composition including the microorganism for preventing or treating a disease causing damage to the gastrointestinal tract.

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

The present invention relates to the technical field of polypeptide drug preparation methods. Provided is a solid-phase preparation method for high-yield and high-purity tirzepatide. An amino resin is used as a starting resin; amino acids and small-fragment peptides are sequentially coupled according to the amino acid sequence of tirzepatide using a solid-phase synthesis method to synthesize a tirzepatide resin; and the tirzepatide resin is cleaved and purified to obtain a pure tirzepatide product. The small-fragment peptides include a 1-4 tetrapeptide fragment Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-OH, a 5-6 dipeptide fragment Fmoc-Thr(tBu)-Phe-OH, a 7-8 dipeptide fragment Fmoc-Thr(tBu)-Ser(tBu)-OH, a 10-11 dipeptide fragment Fmoc-Tyr(tBu)-Ser(tBu)-OH, a 12-13 dipeptide fragment Fmoc-Ile-Aib-OH, a 17-18 dipeptide fragment Fmoc-Ile-Ala-OH, a 20-side-chain peptide Fmoc-Lys(AEEA-AEEA-γ-Glu(α-OtBu)-Eicosanedioic acid(mon-tBu))-OH, a 28-30 tripeptide fragment Fmoc-Ala-Gly-Gly-OH, a 32-34 tripeptide fragment Fmoc-Ser(tBu)-Ser(tBu)-Gly-OH, and a 36-38 tripeptide fragment Fmoc-Pro-Pro-Pro-OH. A coupling agent for coupling the amino acid and the small-fragment peptide is selected from Oxyma and DIC, TPTU and TMP, or COMU and DIEA.

The present disclosure relates to a VIP antagonist for use in the management of the treatment or prevention of cancer and viral infections. In certain embodiments, the present disclosure relates to chimeric variants of VIP antagonists, such as the peptides disclosed herein, and pharmaceutical compositions comprising the same. In certain embodiments, the present disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells with a peptide disclosed herein in vitro and further administering an effective amount of the stimulated immune cells to a subject in need of cancer treatment.

A recombinant protein comprising multiple multi-peptide sets includes first through fifth sequencing primers and first through fourth multi-peptide regions. The first multi-peptide region is between the first and the second sequencing primers. The second multi-peptide region is between the second and the third sequencing primers. The third multi-peptide region is between the third and the fourth sequencing primers. The fourth multi-peptide region is between the fourth and the fifth sequencing primers. In each of the multi-peptide regions, multiple functional peptides can be inserted, and manufacturing thereof can be done through expression of the recombinant protein, thereby significantly enhancing the concentrations of the functional peptides. With the combination of peptide having different functions, the recombinant protein product can provide more complete and more comprehensive functionality. This application also discloses a pharmaceutical composition comprising the recombinant protein and a method for preparing the recombinant protein.

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

A Fusion Peptide for Activation of the APJ and / or GLP-1 Receptors This invention relates to a fusion peptide comprising a GLP-1 receptor agonist (GLP-1 RA) and an APJ receptor agonist; wherein the GLP-1 RA is covalently linked to the APJ receptor agonist by a link; and wherein the fusion peptide retains at least some activity of at least one of the GLP-1 RA and the APJ receptor agonist.

The present invention relates to a novel therapeutic agent for brain diseases and its use. The peptide or pharmaceutical composition of the present invention has a high blood-brain barrier penetration level, which can enhance delivery and reach to the site of action (particularly, inflammatory sites in the brain), and can increase the blood half-life. Furthermore, by improving inflammation levels, it is possible to reduce inflammation and treat or prevent brain diseases.

Glycopeptide analogs of secretin family peptides, including PACAP and VIP, are described herein. These glycopeptides analogs can have neuroprotective properties and enhanced ability to cross the blood brain barrier (BBB) and / or enhanced stability. These glycosylated peptides can be used as drugs for treatment of CNS disorders, such as Parkinson's disease.

Disclosed are POEGMA copolymer conjugates that have phase transition behavior and a reduced or eliminated host-immune response. An example conjugate includes a biologically active agent and a copolymer of POEGMA conjugated to the biologically active agent where the conjugate has a transition temperature. The POEGMA copolymer conjugates can form drug releasing depots, which can be useful in methods of treating diseases.

The invention discloses a circular RNA vaccine based on a vasoactive intestinal peptide delivery system and application of the circular RNA vaccine, and relates to the field of RNA vaccines. Comprising vasoactive intestinal peptide VIP serving as a delivery carrier and circular RNA for coding a respiratory syncytial virus RSVpreF antigen, and the vasoactive intestinal peptide VIP and the circular RNA form a compound through non-covalent linkage; the vasoactive intestinal peptide VIP is a VIP-EGFP-N fusion protein. According to the invention, the function of the VIP as a high-efficiency cell-penetrating peptide is explored and verified for the first time, and the VIP is combined with a circular RNA molecule of a coding RSV key antigen protein preF to construct a safe, stable and high-efficiency RSV vaccine, so that the technical bottlenecks of poor stability of the existing mRNA vaccine, complex and low-efficiency LNP delivery system, insufficient immunogenicity or poor safety of the traditional RSV vaccine and the like are solved.

The present invention relates to compositions comprising a glucagon derivative and a dual agonist of the GLP-1 receptor and GIP receptor, and uses thereof.

A culture method for producing dual-function proteins with improved pharmacokinetic parameters, high stability, low potential for aggregation to form complexes, and reduced potential for immunogenicity is provided. [Solution] A method for producing a recombinant dual-function protein from a mammalian host cell transformed with an expression vector containing a cDNA encoding the dual-function protein or its derivative, comprising culturing the mammalian host cell in a culture medium supplemented with dextran sulfate, wherein the dual-function protein comprises a fibroblast growth factor 21 (FGF21) mutant protein; a biologically active protein, or a mutant or fragment thereof; and an immunoglobulin Fc region, wherein the FGF21 mutant protein comprises substitutions of some amino acids in the amino acid sequence and amino acid mutations to reduce the immunogenicity of the FGF21 protein.

A fusion protein is provided that simultaneously blocks the calcitonin gene-related peptide (CGRP) pathway and the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, and the fusion protein comprises at least one single-domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein simultaneously blocks the CGRP and PACAP pathways, thereby improving the response rate of drugs for the treatment of migraine.

The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.

A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

The present invention relates to a novel brain disease therapeutic and a use thereof. A peptide or pharmaceutical composition according to the present invention can increase the level of delivery to a target site (in particular, inflamed areas of the brain) due to having a high blood-brain barrier penetration level, can have an increased half-life in the bloodstream, and can exhibit anti-inflammatory activity and treat or prevent brain diseases by reducing the level of inflammation.

This invention relates to the technical field of polypeptide drug preparation methods, and provides a solid-phase preparation method for telpoeptide. Using an amino resin as the starting resin, a telpoeptide resin is synthesized by sequentially coupling amino acids and small peptide fragments according to the amino acid sequence of the telpoeptide using a solid-phase synthesis method. The telpoeptide resin is then cleaved and purified to obtain pure telpoeptide. The small peptide fragments are: 1-4 tetrapeptide fragments Boc-Tyr(tBu)-Aib-Glu(OtBu)-G1y-OH; 5-6 dipeptide fragments Fmoc-Thr(tBu)-Phe-OH; 7-8 dipeptide fragments Fmoc-Thr(tBu)-Ser(tBu)-OH; 10-11 dipeptide fragments Fmoc-Tyr(tBu)-Ser(tBu)-OH; 12-13 dipeptide fragments Fmoc-Ile-Aib-OH; 17-18 dipeptide fragments Fmoc-Ile-Ala-OH; and 20 side chain peptides Fmoc-Lys(AEEA-AEEA-γ-Glu(α-OtBu)-Eicosanedioic The peptides consist of the following fragments: acid(mon-tBu)-OH, tripeptide fragments 28-30 (Fmoc-Ala-Gly-Gly-OH), tripeptide fragments 32-34 (Fmoc-Ser(tBu)-Ser(tBu)-Gly-OH), and tripeptide fragments 36-38 (Fmoc-Pro-Pro-Pro-OH); the coupling agent for conjugating the amino acid and the small peptide fragment is selected from Oxyma and DIC, TPTU and TMP, or COMU and DIEA. The crude telpolide prepared by the method of this invention has high yield and high purity.

The present application relates to a kind of cleavage spray precipitation condensing system and the method for removing trifluoroacetic acid, mainly solve the technical problem that the method for generally removing trifluoroacetic acid is not safe, dangerous, inefficient, very slow speed.The trifluoroacetic acid and cleavage mixed solution are transported to cleavage container by solvent input system, and polypeptide resin is added to cleavage container, and stirring device mixes trifluoroacetic acid / cleavage mixed solution and polypeptide resin clockwise or counterclockwise at suitable polypeptide temperature, after cleavage, trifluoroacetic acid / cleavage mixed solution and polypeptide resin are filtered by container filter plate and are transported by solvent delivery pipe to the nozzle of spray precipitation container, nozzle is heated by pressurized hot nitrogen, trifluoroacetic acid / cleavage mixed solution / polypeptide resin and nitrogen are sprayed at the end of nozzle, gasified trifluoroacetic acid is sprayed, residual concentrated pulp-like polypeptide resin is precipitated in spray precipitator, and trifluoroacetic acid gas is condensed after passing through condenser and is input into trifluoroacetic acid collector.